California Supreme Court rejects duty to innovate in Gilead Tenofovir cases
In Gilead Tenofovir Cases, 20 Cal. 5th 390 (2026), the California Supreme Court reportedly held a manufacturer cannot be liable for not developing a safer alternative sooner when the product sold is not defective.
The California Supreme Court, in Gilead Tenofovir Cases, 20 Cal. 5th 390 (2026), rejected the proposition that a pharmaceutical manufacturer may be liable for failing to bring an allegedly safer drug to market sooner when the product it already sells is not defective. Per a Husch Blackwell client alert published on JD Supra on 2 November 2026, the court declined to impose either a duty to innovate or an obligation to accelerate development of alternatives to non-defective products.
The ruling matters well beyond the named parties. If a duty to innovate were recognised, plaintiffs in product-liability and mass-tort litigation could convert regulatory-compliance and portfolio decisions into a continuing legal obligation, expanding discovery, expert scrutiny and settlement pressure across the industry. Manufacturers of drugs, devices and other regulated products typically face strict liability premised on defect; a decision narrowing the routes by which non-defect-based liability can attach to an already marketed product is a meaningful constraint on plaintiff-side case selection in California and on litigation strategy in California venues, with persuasive spillover to other state courts weighing similar theories.
Practical next steps for counsel: obtain and read the opinion rather than the alert summary, assess how its reasoning is applied to design-defect and failure-to-warn claims, and monitor early appellate treatment in California and elsewhere, along with any regulatory or legislative response.